598 Endocr<strong>in</strong>e Reviews, October 2003, 24(5):571–599 Thomas et al. • <strong>Gastro<strong>in</strong>test<strong>in</strong>al</strong> <strong>Hormones</strong> <strong>and</strong> <strong>Proliferation</strong>283. Nesl<strong>and</strong> JM, Holm R, Johannessen JV, Gould VE 1986 Neuronespecific enolase immunosta<strong>in</strong><strong>in</strong>g <strong>in</strong> <strong>the</strong> diagnosis <strong>of</strong> breast carc<strong>in</strong>omaswith neuroendocr<strong>in</strong>e differentiation. Its usefulness <strong>and</strong> limitations.J Pathol 148:35–43284. Reubi JC, Schaer JC, Waser B 1997 Cholecystok<strong>in</strong><strong>in</strong>(CCK)-A<strong>and</strong> CCK-B/gastr<strong>in</strong> receptors <strong>in</strong> human tumors. Cancer Res 57:1377–1386285. Bajo AM, Schally AV, Krupa M, Hebert F, Groot K, SzepeshaziK 2002 Bombes<strong>in</strong> antagonists <strong>in</strong>hibit growth <strong>of</strong> MDA-MB-435 estrogen-<strong>in</strong>dependentbreast cancers <strong>and</strong> decrease <strong>the</strong> expression <strong>of</strong><strong>the</strong> ErbB-2/HER-2 oncoprote<strong>in</strong> <strong>and</strong> c-jun <strong>and</strong> c-fos oncogenes. ProcNatl Acad Sci USA 99:3836–3841286. Thomas F, Arvelo F, Anto<strong>in</strong>e E, Jacrot M, Poupon MF 1992 Antitumoralactivity <strong>of</strong> bombes<strong>in</strong> analogues on small cell lung cancerxenografts: relationship with bombes<strong>in</strong> receptor expression. CancerRes 52:4872–4877287. Cuttitta F, Carney DN, Mulsh<strong>in</strong>e J, Moody TW, Fedorko J,Fischler A, M<strong>in</strong>na JD 1985 Bombes<strong>in</strong>-like peptides can function asautocr<strong>in</strong>e growth factors <strong>in</strong> human small-cell lung cancer. Nature316:823–826288. Chaudhry A, Carrasquillo JA, Avis IL, Shuke N, Reynolds JC,Bartholomew R, Larson SM, Cuttitta F, Johnson BE, Mulsh<strong>in</strong>e JL1999 Phase I <strong>and</strong> imag<strong>in</strong>g trial <strong>of</strong> a monoclonal antibody directedaga<strong>in</strong>st gastr<strong>in</strong>-releas<strong>in</strong>g peptide <strong>in</strong> patients with lung cancer. Cl<strong>in</strong>Cancer Res 5:3385–3393289. Giladi E, Nagalla SR, Sp<strong>in</strong>del ER 1993 Molecular clon<strong>in</strong>g <strong>and</strong>characterization <strong>of</strong> receptors for <strong>the</strong> mammalian bombes<strong>in</strong>-likepeptides. J Mol Neurosci 4:41–54290. Lacroix J, Becker HD, Woerner SM, Rittgen W, Dr<strong>in</strong>gs P, vonKnebel Doeberitz M 2001 Sensitive detection <strong>of</strong> rare cancer cells<strong>in</strong> sputum <strong>and</strong> peripheral blood samples <strong>of</strong> patients with lungcancer by preproGRP-specific RT-PCR. Int J Cancer 92:1–8291. Shibayama T, Ueoka H, Nishii K, Kiura K, Tabata M, MiyatakeK, Kitajima T, Harada M 2001 Complementary roles <strong>of</strong> progastr<strong>in</strong>-releas<strong>in</strong>gpeptide (ProGRP) <strong>and</strong> neuron specific enolase(NSE) <strong>in</strong> diagnosis <strong>and</strong> prognosis <strong>of</strong> small-cell lung cancer (SCLC).Lung Cancer 32:61–69292. Siegfried JM, Han YH, DeMichele MA, Hunt JD, Gai<strong>the</strong>r AL,Cuttitta F 1994 Production <strong>of</strong> gastr<strong>in</strong>-releas<strong>in</strong>g peptide by a nonsmallcell lung carc<strong>in</strong>oma cell l<strong>in</strong>e adapted to serum-free <strong>and</strong>growth factor-free conditions. J Biol Chem 269:8596–8603293. Moody TW, Chiles J, Casibang M, Moody E, Chan D, Davis TP2001 SR48692 is a neurotens<strong>in</strong> receptor antagonist which <strong>in</strong>hibits<strong>the</strong> growth <strong>of</strong> small cell lung cancer cells. Peptides 22:109–115294. Moody TW, Carney DN, Korman LY, Gazdar AF, M<strong>in</strong>na JD 1985Neurotens<strong>in</strong> is produced by <strong>and</strong> secreted from classic small celllung cancer cells. Life Sci 36:1727–1732295. Yashi M, Muraishi O, Kobayashi Y, Tokue A, Nanjo H 2002Elevated serum progastr<strong>in</strong>-releas<strong>in</strong>g peptide (31–98) <strong>in</strong> metastatic<strong>and</strong> <strong>and</strong>rogen-<strong>in</strong>dependent prostate cancer patients. Prostate 51:84–97296. Sehgal I, Powers S, Huntley B, Powis G, Pittelkow M, Maihle NJ1994 Neurotens<strong>in</strong> is an autocr<strong>in</strong>e trophic factor stimulated by <strong>and</strong>rogenwithdrawal <strong>in</strong> human prostate cancer. Proc Natl Acad SciUSA 91:4673–4677297. Seethalakshmi L, Mitra SP, Dobner PR, Menon M, Carraway RE1997 Neurotens<strong>in</strong> receptor expression <strong>in</strong> prostate cancer cell l<strong>in</strong>e<strong>and</strong> growth effect <strong>of</strong> NT at physiological concentrations. Prostate31:183–192298. Dal Farra C, Sarret P, Navarro V, Botto JM, Mazella J, V<strong>in</strong>cent JP2001 Involvement <strong>of</strong> <strong>the</strong> neurotens<strong>in</strong> receptor subtype NTR3 <strong>in</strong> <strong>the</strong>growth effect <strong>of</strong> neurotens<strong>in</strong> on cancer cell l<strong>in</strong>es. Int J Cancer92:503–509299. P<strong>in</strong>ski J, Reile H, Halmos G, Groot K, Schally AV 1994 Inhibitoryeffects <strong>of</strong> somatostat<strong>in</strong> analogue RC-160 <strong>and</strong> bombes<strong>in</strong>/gastr<strong>in</strong>releas<strong>in</strong>gpeptide antagonist RC-3095 on <strong>the</strong> growth <strong>of</strong> <strong>the</strong><strong>and</strong>rogen-<strong>in</strong>dependent Dunn<strong>in</strong>g R-3327-AT-1 rat prostate cancer.Cancer Res 54:169–174300. Jungwirth A, P<strong>in</strong>ski J, Galvan G, Halmos G, Szepeshazi K, CaiRZ, Groot K, Vadillo-Buenfil M, Schally AV 1997 Inhibition <strong>of</strong>growth <strong>of</strong> <strong>and</strong>rogen-<strong>in</strong>dependent DU-145 prostate cancer <strong>in</strong> vivo bylute<strong>in</strong>is<strong>in</strong>g hormone-releas<strong>in</strong>g hormone antagonist Cetrorelix <strong>and</strong>bombes<strong>in</strong> antagonists RC-3940-II <strong>and</strong> RC-3950-II. Eur J Cancer33:1141–1148301. Davis S, Rogers MA, Pendergrass TW 1987 The <strong>in</strong>cidence <strong>and</strong>epidemiologic characteristics <strong>of</strong> neuroblastoma <strong>in</strong> <strong>the</strong> UnitedStates. Am J Epidemiol 126:1063–1074302. Joshi VV, Silverman JF 1994 Pathology <strong>of</strong> neuroblastic tumors.Sem<strong>in</strong> Diagn Pathol 11:107–117303. Kelly DR, Joshi VV 1996 Neuroblastoma <strong>and</strong> related tumors. In:Parham DM, ed. Pediatric neoplasia: morphology <strong>and</strong> biology.Philadelphia: Lipp<strong>in</strong>cott-Raven; 105–152304. Borgstrom P, Hassan M, Wassberg E, Refai E, Jonsson C, Larsson,SA, Jacobsson H, Kogner P 1999 The somatostat<strong>in</strong> analogueoctreotide <strong>in</strong>hibits neuroblastoma growth <strong>in</strong> vivo. Pediatr Res 46:328–332305. Cattaneo MG, Scita G, Vicent<strong>in</strong>i LM 1999 Somatostat<strong>in</strong> <strong>in</strong>hibitsPDGF-stimulated Ras activation <strong>in</strong> human neuroblastoma cells.FEBS Lett 459:64–68306. Schill<strong>in</strong>g FH, Ambros PF, Bihl H, Mart<strong>in</strong>sson T, Ambros IM,Borgstrom P, Jacobsson H, Falkmer UG, Treuner J, Kogner P 2001Absence <strong>of</strong> somatostat<strong>in</strong> receptor expression <strong>in</strong> vivo is correlated todi- or tetraploid 1p36-deleted neuroblastomas. Med Pediatr Oncol36:56–60307. Orl<strong>and</strong>o C, Raggi CC, Bagnoni L, Sest<strong>in</strong>i R, Briganti V, La CavaG, Bern<strong>in</strong>i G, Ton<strong>in</strong>i GP, Pazzagli M, Serio M, Maggi M 2001Somatostat<strong>in</strong> receptor type 2 gene expression <strong>in</strong> neuroblastoma,measured by competitive RT-PCR, is related to patient survival <strong>and</strong>to somatostat<strong>in</strong> receptor imag<strong>in</strong>g by <strong>in</strong>dium-111-pentetreotide.Med Pediatr Oncol 36:224–226308. Sebesta JA, Young A, Bullock J, Moore KH, Azarow K, Saw<strong>in</strong> RS2001 Gastr<strong>in</strong>-releas<strong>in</strong>g peptide: a potential growth factor expressed<strong>in</strong> human neuroblastoma tumors(1). Curr Surg 58:86–89309. Kim S, Hu W, Kelly DR, Hellmich MR, Evers BM, Chung DH2002 Gastr<strong>in</strong>-releas<strong>in</strong>g peptide is a growth factor for human neuroblastomas.Ann Surg 235:621–630310. Thompson JC, Townsend Jr CM 2001 Endocr<strong>in</strong>e pancreas. In:Townsend Jr CM, Beauchamp RD, Evers BM, Mattox KL, eds.Sabiston textbook <strong>of</strong> surgery: <strong>the</strong> biological basis <strong>of</strong> modern surgicalpractice. 16th ed. Philadelphia: W. B. Saunders Company;646–661311. Angood PB, G<strong>in</strong>galewski CA, Andersen DK 2001 Surgical complications.In: Townsend Jr CM, Beauchamp RD, Evers BM, MattoxKL, eds. Sabiston textbook <strong>of</strong> surgery: <strong>the</strong> biological basis <strong>of</strong> modernsurgical practice, 16th ed. Philadelphia: W. B. Saunders Company;198–225312. Oberg K 2001 Chemo<strong>the</strong>rapy <strong>and</strong> bio<strong>the</strong>rapy <strong>in</strong> <strong>the</strong> treatment <strong>of</strong>neuroendocr<strong>in</strong>e tumours. Ann Oncol 12(Suppl 2):S111–S114313. Schmassmann A, Reubi JC 2000 Cholecystok<strong>in</strong><strong>in</strong>-B/gastr<strong>in</strong> receptorsenhance wound heal<strong>in</strong>g <strong>in</strong> <strong>the</strong> rat gastric mucosa. J Cl<strong>in</strong>Invest 106:1021–1029314. Scolapio JS 2001 Treatment <strong>of</strong> short-bowel syndrome. Curr Op<strong>in</strong>Cl<strong>in</strong> Nutr Metab Care 4:557–560315. Toledano A, Rodriguez-Arellano JJ, Gomez de Segura IA,De Miguel E, Mart<strong>in</strong>ez-Rodriguez R 1996 Bowel resection <strong>and</strong>neurotens<strong>in</strong> treatment. Histochemical study <strong>of</strong> neurotens<strong>in</strong>-like<strong>and</strong> somatostat<strong>in</strong>-like immunoreactivities <strong>and</strong> receptors. Cell MolBiol (Noisy-le-gr<strong>and</strong>) 42:1145–1158316. Jeppesen PB, Hartmann B, Thulesen J, Graff J, Lohmann J,Hansen BS, T<strong>of</strong>teng F, Poulsen SS, Madsen JL, Holst JJ,Mortensen PB 2001 Glucagon-like peptide 2 improves nutrientabsorption <strong>and</strong> nutritional status <strong>in</strong> short-bowel patients with nocolon. Gastroenterology 120:806–815317. Smith AM, Just<strong>in</strong> T, Michaeli D, Watson SA 2000 Phase I/II study<strong>of</strong> G17-DT, an anti-gastr<strong>in</strong> immunogen, <strong>in</strong> advanced colorectalcancer. Cl<strong>in</strong> Cancer Res 6:4719–4724318. Watson SA, Michaeli D, Morris TM, Clarke P, Varro A, Griff<strong>in</strong>N, Smith A, Just<strong>in</strong> T, Hardcastle JD 1999 Antibodies raised bygastrimmune <strong>in</strong>hibit <strong>the</strong> spontaneous metastasis <strong>of</strong> a human colorectaltumour, AP5LV. Eur J Cancer 35:1286–1291319. Abbruzzese JL, Gholson CF, Daugherty K, Larson E, DuBrow R,Berl<strong>in</strong> R, Lev<strong>in</strong> B 1992 A pilot cl<strong>in</strong>ical trial <strong>of</strong> <strong>the</strong> cholecystok<strong>in</strong><strong>in</strong>receptor antagonist MK-329 <strong>in</strong> patients with advanced pancreaticcancer. Pancreas 7:165–171320. Militello C, Sperti C, Di Prima F, Pedrazzoli S 1997 Cl<strong>in</strong>icalDownloaded from edrv.endojournals.org by on July 16, 2007
Thomas et al. • <strong>Gastro<strong>in</strong>test<strong>in</strong>al</strong> <strong>Hormones</strong> <strong>and</strong> <strong>Proliferation</strong> Endocr<strong>in</strong>e Reviews, October 2003, 24(5):571–599 599evaluation <strong>and</strong> safety <strong>of</strong> loxiglumide (CCK-A receptor antagonist)<strong>in</strong> nonresectable pancreatic cancer patients. Italian Pancreatic CancerStudy Group. Pancreas 14:222–228321. Hejna M, Schmid<strong>in</strong>ger M, Raderer M 2002 The cl<strong>in</strong>ical role <strong>of</strong>somatostat<strong>in</strong> analogues as ant<strong>in</strong>eoplastic agents: much ado aboutnoth<strong>in</strong>g? Ann Oncol 13:653–668322. Kraenzl<strong>in</strong> ME, Ch’ng JL, Wood SM, Carr DH, Bloom SR 1985Long-term treatment <strong>of</strong> a VIPoma with somatostat<strong>in</strong> analogue result<strong>in</strong>g<strong>in</strong> remission <strong>of</strong> symptoms <strong>and</strong> possible shr<strong>in</strong>kage <strong>of</strong> metastases.Gastroenterology 88:185–187323. Williams G, Anderson JV, Williams SJ, Bloom SR 1987 Cl<strong>in</strong>icalevaluation <strong>of</strong> SMS 201-995. Long-term treatment <strong>in</strong> gut neuroendocr<strong>in</strong>etumours, efficacy <strong>of</strong> oral adm<strong>in</strong>istration, <strong>and</strong> possible use<strong>in</strong> non-tumoural <strong>in</strong>appropriate TSH hypersecretion. Acta Endocr<strong>in</strong>olSuppl (Copenh) 286:26–36324. Ebert M, Friess H, Beger HG, Buchler MW 1994 <strong>Role</strong> <strong>of</strong> octreotide<strong>in</strong> <strong>the</strong> treatment <strong>of</strong> pancreatic cancer. Digestion 55(Suppl 1):48–51325. Goldberg RM, Moertel CG, Wie<strong>and</strong> HS, Krook JE, Schutt AJ,Veeder MH, Mailliard JA, Dalton RJ 1995 A phase III evaluation<strong>of</strong> a somatostat<strong>in</strong> analogue (octreotide) <strong>in</strong> <strong>the</strong> treatment <strong>of</strong>patients with asymptomatic advanced colon carc<strong>in</strong>oma. NorthCentral Cancer Treatment Group <strong>and</strong> <strong>the</strong> Mayo Cl<strong>in</strong>ic. Cancer76:961–966326. Cirillo F, Bott<strong>in</strong>i A, Brunelli A, Zuffada S, Bassi M, Filipp<strong>in</strong>i L,Alquati P 1998 Octreotide <strong>in</strong> <strong>the</strong> treatment <strong>of</strong> advanced pancreatictumor. Prelim<strong>in</strong>ary study. M<strong>in</strong>erva Chir 53:979–9853rd European Congress <strong>of</strong> Andrology/16th Congress <strong>of</strong> <strong>the</strong> German Society <strong>of</strong> AndrologySeptember 11–14, 2004Münster, GermanyThe 3rd ECA will be <strong>the</strong> premier event <strong>in</strong> Andrology <strong>in</strong> 2004 <strong>in</strong> Europe, sponsored by <strong>the</strong> European Academy<strong>of</strong> Andrology (EAA) <strong>and</strong> <strong>the</strong> German Society <strong>of</strong> Andrology (DGA). It br<strong>in</strong>gs toge<strong>the</strong>r cl<strong>in</strong>icians <strong>and</strong> basicscientists active <strong>in</strong> <strong>and</strong>rology <strong>and</strong> will cover all aspects <strong>of</strong> <strong>and</strong>rology with emphasis on control <strong>of</strong> spermatogenesis,spermatogonial stem cells, <strong>the</strong>rapeutic use <strong>of</strong> <strong>and</strong>rogens, erectile dysfunction, male <strong>in</strong>fertility,assisted reproduction, paternally mediated teratogenicity, prostate cancer, testicular tumors, environment<strong>and</strong> reproduction, <strong>and</strong> f<strong>in</strong>ally male contraception.Fur<strong>the</strong>r <strong>in</strong>formation, registration <strong>and</strong> abstract submission through <strong>the</strong> web site: www.3rd-eca.deFur<strong>the</strong>r contact: Pr<strong>of</strong>. Dr. E. Nieschlag, Institute <strong>of</strong> Reproductive Medic<strong>in</strong>e <strong>of</strong> <strong>the</strong> University, D-48129Muenster, Germany, Tel: 49 0251/83 56096, Fax: 49 0251/8356093, E-mail: nieschl@uni-muenster.deIOF World Congress on OsteoporosisThe International Osteoporosis Foundation is pleased to <strong>in</strong>vite you to participate <strong>in</strong> <strong>the</strong> IOF World Congresson Osteoporosis to be held <strong>in</strong> Rio de Janerio (Brazil), May 14–18, 2004. This event is your chance to hear—<strong>and</strong>meet—<strong>the</strong> lead<strong>in</strong>g experts <strong>in</strong> <strong>the</strong> field <strong>and</strong> learn <strong>the</strong> latest developments <strong>in</strong> basic research <strong>and</strong> cl<strong>in</strong>ical <strong>and</strong><strong>the</strong>rapeutic advances. Onl<strong>in</strong>e abstract submission <strong>and</strong> registration can be found at www.oste<strong>of</strong>ound.orgContact: IOF–Congress Secretariat, 71 cours Albert Thomas, 69447 Lyon, France, Tel: 33472914177,Fax: 33 4 72 36 90 52, E-mail: <strong>in</strong>fo@oste<strong>of</strong>ound.orgDownloaded from edrv.endojournals.org by on July 16, 2007
Change language